PIII Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -12.84% compared to P3 Health Partners's net margin of 1.08%. P3 Health Partners's return on equity of -26.35% beat Astrana Health's return on equity of 7.09%.

P3 Health Partners has a consensus price target of $16.25, signalling upside risk potential of 98.41%. On the other hand Astrana Health has an analysts' consensus of $50.3000 which suggests that it could grow by 88.39%. Given that P3 Health Partners has higher upside potential than Astrana Health, analysts believe P3 Health Partners is more attractive than Astrana Health.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.209%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

P3 Health Partners quarterly revenues are $362.1M, which are smaller than Astrana Health quarterly revenues of $620.4M. P3 Health Partners's net income of -$46.5M is lower than Astrana Health's net income of $6.7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Astrana Health's PE ratio is 37.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 0.57x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of -12.84% compared to P3 Health Partners's net margin of 28%. P3 Health Partners's return on equity of -26.35% beat Biote's return on equity of --.

P3 Health Partners has a consensus price target of $16.25, signalling upside risk potential of 98.41%. On the other hand Biote has an analysts' consensus of $7.00 which suggests that it could grow by 70.46%. Given that P3 Health Partners has higher upside potential than Biote, analysts believe P3 Health Partners is more attractive than Biote.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend.

P3 Health Partners quarterly revenues are $362.1M, which are larger than Biote quarterly revenues of $49M. P3 Health Partners's net income of -$46.5M is lower than Biote's net income of $13.7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Biote's PE ratio is 6.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 0.68x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -12.84% compared to P3 Health Partners's net margin of 3.55%. P3 Health Partners's return on equity of -26.35% beat Cryo-Cell International's return on equity of --.

P3 Health Partners has a consensus price target of $16.25, signalling upside risk potential of 98.41%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 68.4%. Given that P3 Health Partners has higher upside potential than Cryo-Cell International, analysts believe P3 Health Partners is more attractive than Cryo-Cell International.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.595%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 9.91% to investors and pays a quarterly dividend of $0.25 per share. P3 Health Partners pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

P3 Health Partners quarterly revenues are $362.1M, which are larger than Cryo-Cell International quarterly revenues of $8M. P3 Health Partners's net income of -$46.5M is lower than Cryo-Cell International's net income of $282.9K. Notably, P3 Health Partners's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 504.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 1.29x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of -12.84% compared to P3 Health Partners's net margin of -2.6%. P3 Health Partners's return on equity of -26.35% beat Omnicell's return on equity of 1.73%.

P3 Health Partners has a consensus price target of $16.25, signalling upside risk potential of 98.41%. On the other hand Omnicell has an analysts' consensus of $37.83 which suggests that it could grow by 32.74%. Given that P3 Health Partners has higher upside potential than Omnicell, analysts believe P3 Health Partners is more attractive than Omnicell.

P3 Health Partners has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omnicell has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.397%.

P3 Health Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. P3 Health Partners pays -- of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

P3 Health Partners quarterly revenues are $362.1M, which are larger than Omnicell quarterly revenues of $269.7M. P3 Health Partners's net income of -$46.5M is lower than Omnicell's net income of -$7M. Notably, P3 Health Partners's price-to-earnings ratio is -- while Omnicell's PE ratio is 60.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for P3 Health Partners is 0.02x versus 1.15x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.